APA način citiranja

Wang, S., Xing, P., Yang, K., Hao, X., Ma, D., Mu, Y., & Li, J. (2019). Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thorac Cancer.

Čikaški stil citiranja

Wang, Shouzheng, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, i Junling Li. "Efficacy and Safety of Afatinib in a Chinese Population With Advanced Lung Adenocarcinoma With Sensitive EGFR Mutations." Thorac Cancer 2019.

MLA način citiranja

Wang, Shouzheng, et al. "Efficacy and Safety of Afatinib in a Chinese Population With Advanced Lung Adenocarcinoma With Sensitive EGFR Mutations." Thorac Cancer 2019.